Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human MET/c-Met/HGFR Antibody (SAA0111)

Catalog #:   FHC34210 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG4, kappa
Applications: FCM
Accession: P08581
Overview

Catalog No.

FHC34210

Species reactivity

Human

Host species

Human

Isotype

IgG4, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08581

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0111

Data Image
  • Flow-cytometry
    Flow-cytometry using anti-human c-Met antibody.HeLa cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human c-Met antibody monoclonal antibody (Catalog # FHC34210 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # PHB96441) and cells analysed on a NovoCyte Flow Cytometer.
  • Flow-cytometry
    Flow-cytometry using anti-human c-Met antibody.HepG2 cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human c-Met antibody monoclonal antibody (Catalog # FHC34210 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # PHB96441) and cells analysed on a NovoCyte Flow Cytometer.
  • Flow-cytometry
    Flow-cytometry using anti-human c-Met antibody.HT-29 cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human c-Met antibody monoclonal antibody (Catalog # FHC34210 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # PHB96441) and cells analysed on a NovoCyte Flow Cytometer.
References

Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders., PMID:40505071

The use of Bevacizumab in the treatment of brain arteriovenous malformations: a systematic review., PMID:40504282

IFITM3 deficient mice as a model for testing influenza virus vaccines., PMID:40501891

Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study., PMID:40501126

Impact of Universal Screening for HDV in HBV-Infected Patients on Chronic HDV Detection Rate in Israel., PMID:40497662

Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review., PMID:40497133

Anti-NMDAR Encephalitis With Serial Negative MRI Findings: An Evaluation Using Autoimmune Psychosis Criteria., PMID:40496240

Induction With Antithymocyte Globulin Is Associated With Decreased Mortality and PTLD in Pediatric Liver Transplantation: A UNOS Data Analysis., PMID:40490923

Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma., PMID:40489635

Impact of sirtuin‑1 expression on progression‑free survival in non‑endometrioid endometrial cancer: A retrospective cohort study., PMID:40486084

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial., PMID:40483169

Tumefactive demyelination as the first presentation of MOG ab-associated disease., PMID:40479755

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial., PMID:40474841

Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022., PMID:40473981

Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies., PMID:40471555

A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors., PMID:40465170

Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years., PMID:40464662

Effects of cottonseed meal bioactive peptides on growth performance, ileal digestibility, serum amino acid and immune responses of broiler chickens., PMID:40464591

Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility., PMID:40463399

Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data., PMID:40462491

Association of cancer and anti-synthetase syndrome: a retrospective multicentre study., PMID:40460913

Genetics in a Danish Common Variable Immunodeficiency Cohort., PMID:40455168

Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial., PMID:40450141

Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial., PMID:40450051

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial., PMID:40447851

Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer., PMID:40446773

The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment., PMID:40445574

Clinical spectrum and long-term outcomes of antibody-negative severe autoimmune encephalitis: a retrospective study., PMID:40443652

Adverse Cutaneous Reactions to Monoclonal Antibodies: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Erythema Multiforme, and Fixed Drug Eruption - A Systematic Review., PMID:40443459

Serum antineuronal antibodies in patients with post-COVID-19 condition - association to intensive care., PMID:40441540

PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis., PMID:40440581

Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer., PMID:40440007

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib., PMID:40439479

Incidence of catheter-related bloodstream infection (CRBSI) in immunosuppressed hosts post solid organ transplant (SOT): a single center experience., PMID:40438131

Latin American RAND/UCLA modified Delphi consensus recommendations for management and treatment of adult MOGAD patients in clinical practice., PMID:40435656

The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial., PMID:40432079

Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials., PMID:40430899

Q Fever-Related Community Infections: United States Exposure to Coxiella burnetii., PMID:40430780

Cellular Metabolic Disorders in a Cohort of Patients with Sjogren's Disease., PMID:40429812

High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease., PMID:40424081

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study., PMID:40413619

Systematic Literature Review of DOACs as Treatment for Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)., PMID:40411430

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)., PMID:40410927

A highly specific antibody profiled by hapten prediction and its application in an immunoassay for Anilazine., PMID:40408967

Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis., PMID:40408051

Design of heavy chain antibody-drug conjugates targeting c-Met to eradicate lung adenocarcinoma giant tumors with a single-dose., PMID:40404557

Unilateral Graves' disease: a case report with concomitant thyroid cancer and systematic review of literature., PMID:40401585

Unique characteristics of autoantibodies targeting MET in patients with breast and lung cancer., PMID:40401526

Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma., PMID:40397297

Datasheet
$ 225
Product specifications
50 μg 225 100 μg 372

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human MET/c-Met/HGFR Antibody (SAA0111) [FHC34210]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only